Fuchs R P, Koffel-Schwartz N, Pelet S, Janel-Bintz R, Napolitano R, Becherel O J, Broschard T H, Burnouf D Y, Wagner J
UPR 9003, CNRS Cancerogenese et Mutagenese Moleculaire et Structurale, ESBS and IRCAD, Strasbourg 67400, France.
Biochem Soc Trans. 2001 May;29(Pt 2):191-5. doi: 10.1042/0300-5127:0290191.
The NarI sequence represents a strong mutation hot spot for -2 frameshift mutations induced by N-2-acetylaminofluorene (AAF), a strong chemical carcinogen. Only when bound to the third (underlined) guanine (5'-GGCGCC-->GGCC) can AAF trigger frameshift mutations, suggesting the involvement of a slipped replication intermediate with a two-nucleotide bulge. While base substitutions induced by UV light or abasic sites require DNA polymerase V (Pol V; umuDC), the AAF-induced -2 frameshift pathway requires DNA polymerase II, the polB gene product. Interestingly, error-free bypass of the G-AAF adduct requires Pol V. The genes encoding both Pol II and Pol V are induced by the SOS regulon, a co-ordinated cellular response to environmental stress. A given lesion, G-AAF, can thus be bypassed by two SOS-controlled DNA polymerases (II and V), generating mutagenic (-2 frameshifts) and error-free replication products respectively. Therefore both Pol II and Pol V can compete for the blocked replication intermediate in the vicinity of the lesion and engage in replication by transiently replacing the replicative DNA Pol III. Our data suggest that, in order to cope with the large diversity of existing DNA lesions, cells use a single or a combination of translesional DNA polymerases to achieve translesion synthesis.
NarI序列是由强化学致癌物N-2-乙酰氨基芴(AAF)诱导产生-2移码突变的一个强突变热点。只有当AAF与第三个(下划线标注的)鸟嘌呤结合时(5'-GGCGCC-->GGCC),它才能引发移码突变,这表明存在一个带有两个核苷酸凸起的滑动复制中间体参与其中。虽然紫外线或无碱基位点诱导的碱基替换需要DNA聚合酶V(Pol V;umuDC),但AAF诱导的-2移码途径需要DNA聚合酶II,即polB基因产物。有趣的是,G-AAF加合物的无错绕过需要Pol V。编码Pol II和Pol V的基因均由SOS调控子诱导产生,SOS调控子是细胞对环境应激的一种协调反应。因此,一个特定的损伤,即G-AAF,可以被两种受SOS控制的DNA聚合酶(II和V)绕过,分别产生诱变的(-2移码)和无错的复制产物。所以,Pol II和Pol V都可以在损伤附近竞争受阻的复制中间体,并通过暂时取代复制性DNA聚合酶III来进行复制。我们的数据表明,为了应对现有的大量不同的DNA损伤,细胞使用一种或多种跨损伤DNA聚合酶的组合来实现跨损伤合成。